Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson’s disease

5Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Lysosomal dysfunction has been associated with Parkinson’s disease (PD). However, the activity of lysosomal enzymes is heterogeneously observed in PD. We investigated whether arylsulfatase A (ARSA) level can be used as a fluid biomarker of PD and can reflect disease progression. Plasma ARSA level was measured in 55 patients with early and drug-naïve PD, 13 patients with late PD, and 14 healthy controls. We compared the plasma ARSA level among the groups and assessed its correlation to clinical parameters and striatal dopamine transporter (DAT) activity. Plasma ARSA level was not correlated with age. The early PD group had higher plasma ARSA level than the control and late PD groups. In a generalized additive model including all patients with PD, the plasma ARSA level showed an inverted U-shape according to disease duration, peaking at 2.19 years. In patients with early PD, plasma ARSA level was positively correlated to parkinsonian motor score and negatively to striatal DAT activity. In summary, plasma ARSA level was elevated in early stage of PD, and elevated plasma ARSA level was correlated to the clinical and imaging markers of nigrostriatal degeneration. These results suggest that ARSA level is a potential biomarker of compensation in early PD.

Cite

CITATION STYLE

APA

Yoo, H. S., Lee, J. S., Chung, S. J., Ye, B. S., Sohn, Y. H., Lee, S. J., & Lee, P. H. (2020). Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson’s disease. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-62536-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free